B. Riley Securities Maintains Buy on ClearPoint Neuro, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

B. Riley Securities analyst Anderson Schock maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $20 to $30.